Frontiers in Immunology (Sep 2023)
Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
- Zhimin Zeng,
- Zhimin Zeng,
- Zhimin Zeng,
- Xiaoying Qian,
- Xiaoying Qian,
- Fanrong Liu,
- Yong Wang,
- Yong Wang,
- Yong Yuan,
- Chen Fang,
- Chen Fang,
- Xinwei Zhang,
- Xinwei Zhang,
- Shangkun Yuan,
- Shangkun Yuan,
- Renfang Chen,
- Renfang Chen,
- Biao Yu,
- Biao Yu,
- Tong Wang,
- Tong Wang,
- Yan Yin,
- Yong Li,
- Yong Li,
- Anwen Liu,
- Anwen Liu,
- Anwen Liu
Affiliations
- Zhimin Zeng
- Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
- Zhimin Zeng
- Jiangxi Key Laboratory of Clinical Translational Cancer Research, Nanchang, Jiangxi, China
- Zhimin Zeng
- Radiation Induced Heart Damage Institute of Nanchang University, Nanchang, Jiangxi, China
- Xiaoying Qian
- Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China
- Xiaoying Qian
- Medical Innovation Center, The First Affiliated Hospital of Nanchang University, Nanchang, China
- Fanrong Liu
- Department of Pathology, The Second Affiliated Hospital of Nanchang University, Nanchang, China
- Yong Wang
- Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China
- Yong Wang
- Medical Innovation Center, The First Affiliated Hospital of Nanchang University, Nanchang, China
- Yong Yuan
- Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China
- Chen Fang
- Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China
- Chen Fang
- Medical Innovation Center, The First Affiliated Hospital of Nanchang University, Nanchang, China
- Xinwei Zhang
- Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China
- Xinwei Zhang
- Medical Innovation Center, The First Affiliated Hospital of Nanchang University, Nanchang, China
- Shangkun Yuan
- Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China
- Shangkun Yuan
- Medical Innovation Center, The First Affiliated Hospital of Nanchang University, Nanchang, China
- Renfang Chen
- Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China
- Renfang Chen
- Medical Innovation Center, The First Affiliated Hospital of Nanchang University, Nanchang, China
- Biao Yu
- Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China
- Biao Yu
- Medical Innovation Center, The First Affiliated Hospital of Nanchang University, Nanchang, China
- Tong Wang
- Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China
- Tong Wang
- Medical Innovation Center, The First Affiliated Hospital of Nanchang University, Nanchang, China
- Yan Yin
- Department of Pathology, The First Affiliated Hospital of Nanchang University, Nanchang, China
- Yong Li
- Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China
- Yong Li
- Medical Innovation Center, The First Affiliated Hospital of Nanchang University, Nanchang, China
- Anwen Liu
- Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
- Anwen Liu
- Jiangxi Key Laboratory of Clinical Translational Cancer Research, Nanchang, Jiangxi, China
- Anwen Liu
- Radiation Induced Heart Damage Institute of Nanchang University, Nanchang, Jiangxi, China
- DOI
- https://doi.org/10.3389/fimmu.2023.1269596
- Journal volume & issue
-
Vol. 14
Abstract
No abstracts available.Keywords
- pulmonary sarcomatoid carcinoma
- immune checkpoint inhibitors
- immunotherapy
- anlotinib
- camrelizumab
- tislelizumab
